Resveratrol inhibits TNF-α-induced changes of adipokines in 3T3-L1 adipocytes

Biochemical and Biophysical Research Communications

Volumn 364, Issue 4, 2007, Pages 972-977

  Ahn, Jiyun ^a   Lee, Hyunjung ^a   Kim, Suna ^a   Ha, Taeyoul ^a  

^a Korea Food Research Institute   (South Korea)

Author keywords

3T3 L1 adipocyte; Adiponectin; IL 6; PAI 1; Resveratrol

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INTERLEUKIN-6; MICE; SERPINS; STILBENES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

RODENTIA;

EID: 36048974865     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.10.109     Document Type: Article

References (41)

1. Douketis J.D., and Sharma A.M. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin. Vasc. Med. 5 (2005) 25-33
2. James P.T., Rigby N., and Leach R. International Obesity Task Force, The obesity epidemic, metabolic syndrome and future prevention strategies. Eur. J. Cardiovasc. Prev. Rehabil. 11 (2004) 3-8
3. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., Hollenbeck A., and Leitzmann M.F. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N. Engl. J. Med. 355 (2006) 763-778
4. Grundy S.M. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89 (2004) 2595-2600
5. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92 (2004) 347-355
6. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman ML., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
7. Lam K.S., and Xu A. Adiponectin: protection of the endothelium. Curr. Diab. Rep. 5 (2005) 254-259
8. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 29-33
9. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257 (2005) 167-175
10. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., Knowler W.C., and Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
11. Maahs D.M., Ogden L.G., Kinney G.L., Wadwa P., Snell-Bergeon J.K., Dabelea D., Hokanson J.E., Ehrlich J., Eckel R.H., and Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111 (2005) 747-753
12. Lyon C.J., and Hsueh W.A. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am. J. Med. 115 (2003) S62-S68
13. Skurk T., and Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 1357-1364
14. C. Fearns, F. Samad, D.J. Louskutoff, Synthesis and localization of PAI-1 in the vessel wall, in: V.W.M. van Hinsbergh (Eds.), Vascular Contol of Hemostasis, Harwood Academic Publishers, Amsterdam, 1995, pp. 207-226.
15. Juhan-Vague I., Alessi M.C., Mavri A., and Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance, and vascular risk. J. Thromb. Haemost. 1 (2003) 1575-1579
16. Morange P.E., Alessi M.C., Verdier M., Casanova D., Magalon G., and Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1361-1365
17. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., Yamashita S., Miura M., Fukuda Y., Takemura K., Tokunaga K., and Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 2 (1996) 800-803
18. Chen R.S., Wu P.L., and Chiou R.Y.Y. Peanut roots as a source of resveratrol. J. Agric. Food Chem. 50 (2002) 1665-1667
19. Mukamal K.J., Conigrave K.M., Mittleman M.A., Camargo C.A., Stampfer M.J., Willett W.C., and Rimm E.B. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N. Engl. J. Med. 348 (2003) 109-118
20. Manna S.K., Mukhopadhyay A., and Aggarwal B.B. Resveratrol suppresses TNFα-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164 (2000) 6509-6519
21. Olas B., and Wachowicz B. Resveratrol and vitamin C as antioxidants in blood platelets. Thromb. Res. 106 (2002) 143-148
22. Liu J.C., Chen J.J., Chan P., Cheng C.F., and Cheng T.H. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 42 (2003) 1198-1205
23. Sato M., Maulik N., and Das D.K. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann. N. Y. Acad. Sci. 957 (2002) 122-135
24. Green H., and Kehinde O. An established preadipose cell line and its differentiation in culture: II. Factors affecting the adipose conversion. Cell 5 (1975) 19-27
25. Samad F., Loskutoff D.J., and Pandey M. Molecular mechanisms of tumor necrosis factor-α-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J. 19 (2005) 1317-1319
26. Fang J.G., Lu M., Chen Z.H., Zhu H.H., Li Y., Yang L., Wu L.M., and Liu Z.L. Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chemistry 8 (2002) 4191-4198
27. Olas B., Wachowicz B., Saluk-Juszczak J., Zielinski T., Kaca W., and Buczynski A. Antioxidant activity of resveratrol in endotoxin-stimulated blood platelets. Cell Biol. Toxicol. 17 (2001) 117-125
28. Stojanovic S., Sprinz H., and Brede O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch. Biochem. Biophys. 391 (2001) 79-89
29. Murcia M.A., and Martinez-Tome M. Antioxidant activity of resveratrol compared with common food additive. J. Food Prot. 64 (2001) 379-384
30. Burkitt M.J., and Duncan J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel glutathione-sparing mechanism of action. J. Arch. Biochem. Biophys. 381 (2000) 253-263
31. Fremont L., Belguendouz L., and Delpal S. Antioxidant activity of. resveratrol and alcohol-free wine polyphenols related to LDL oxidation and. polyunsaturated fatty acids. Life Sci. 64 (1999) 2511-2521
32. Pinto M.C., Garcia-Barrado J.A., and Macias P. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. J. Agric. Food Chem. 47 (1999) 4842-4846
33. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A., Bertelli A., and Das D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 27 (1999) 160-169
34. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., and Takada S.Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 (2004) 2783-2840
35. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., and Sinclair D.A. Small molecule sirtuin activators that extend S. cerevisiae lifespan. Nature 425 (2003) 191-196
36. Araki T., Sasaki Y., Y, and Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305 (2004) 1010-1013
37. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., and Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776
38. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., and Mayo M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23 (2004) 2369-2380
39. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
40. Quiang L., Wang H., and Farmer S.R. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase ERO1-Lα. Mol. Cell Biol. 27 (2007) 4698-4707
41. Subsaute A.R., and Burant C.F. Role of FoxO1 in FFA-induced oxidative stress in adipocytes. Am. J. Physiol. Endocrinol. Metab. 293 (2007) E159-E164